Skip to main content
main-content

01.03.2012 | Original Article | Ausgabe 3/2012

Cancer Chemotherapy and Pharmacology 3/2012

Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX

Zeitschrift:
Cancer Chemotherapy and Pharmacology > Ausgabe 3/2012
Autoren:
T. Mazard, M. Ychou, S. Thezenas, S. Poujol, F. Pinguet, A. Thirion, J. P. Bleuse, F. Portales, E. Samalin, E. Assenat

Abstract

Background

Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors.

Patients and methods

In this two-step phase I trial, seventeen and eleven patients were enrolled in the XELIRI and XELIRINOX stages, respectively.

Results

In XELIRI, a total of 136 chemotherapy cycles were administered with a median number of 8 cycles per patient (2–16). Main dose-limiting toxicities (DLT) were grade 3–4 neutropenia, with one toxicity-related death. Maximum tolerated dose (MTD) for capecitabine combined with 180 mg/m2 of irinotecan was 3,500 mg/m2/day. In XELIRINOX, capecitabine starting dose was 2,500 mg/m2/day. Fifty-eight chemotherapy cycles were administered with a median of 4 cycles per patient (1–16). DLT included 3 grade 4 neutropenia, associated with 1 grade 3 diarrhea, and 1 grade 4 pneumopathy leading to patient death. MTD for capecitabine with 180 mg/m2 of irinotecan and 85 mg/m2 of oxaliplatin was 3,000 mg/m2/day. The recommended doses for capecitabine were 3,000 and 2,500 mg/m2/day D1–D7 in combination with 180 mg/m2 of irinotecan in XELIRI, plus 85 mg/m2 of oxaliplatin in XELIRINOX (D1 = D14), respectively.

Conclusion

XELIRI and XELIRINOX regimens are feasible and warrant further investigation in combination with targeted therapy in metastatic colorectal cancer patients.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2012

Cancer Chemotherapy and Pharmacology 3/2012 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise